Trump's Psychedelics Executive Order: FDA Priority Vouchers and a $50 Million Federal Push

President Donald Trump signed an executive order on April 18, 2026, directing federal agencies to accelerate access to psychedelic drugs for Americans with serious mental illness. The sweeping directive establishes multiple pathways for faster drug development, including FDA priority review vouchers, Right to Try access, and $50 million in federal funding to support state-level research programs.

The order arrives amid growing research suggesting psychedelics could offer breakthrough treatments for conditions that have resisted conventional therapies, including treatment-resistant depression, post-traumatic stress disorder, and substance use disorders. For the more than 14 million American adults living with serious mental illness—and particularly for veterans, who experience suicide rates more than twice the national average—the policy represents a potential shift in how the federal government approaches mental health innovation.

What the Order Changes

The executive order contains several concrete directives that could reshape the regulatory landscape for psychedelic medicine. FDA Commissioner Marty Makary announced that three priority review vouchers would be issued the following week for serotonin 2a agonist psychedelics, with agency decisions expected later this summer. These vouchers, part of the Commissioner's National Priority Voucher Program, target review timelines of one to two months rather than the standard ten-month process.

The order also instructs the FDA and Drug Enforcement Administration to establish a pathway for eligible patients to access investigational psychedelic drugs under the Right to Try Act. This provision could extend beyond terminally ill patients to include those with serious mental illnesses who have exhausted standard treatment options. The pathway specifically mentions ibogaine compounds, which have shown promise in treating addiction but have faced regulatory hurdles due to cardiac safety concerns.

Federal-State Collaboration

The Department of Health and Human Services is directed to allocate $50 million through the Advanced Research Projects Agency for Health (ARPA-H) to match investments made by state governments advancing psychedelic research. This provision appears designed to encourage and amplify state-level initiatives like Texas's $100 million ibogaine research consortium, which the state launched after failing to find a private partner to match its initial $50 million allocation.

The order further mandates collaboration between HHS, FDA, the Department of Veterans Affairs, and private sector partners to increase clinical trial participation, data sharing, and real-world evidence generation. Data-sharing memoranda are required to ensure information from studies conducted across federal agencies is available to facilitate timely FDA evaluation.

Rescheduling and Enforcement

Attorney General Pam Bondi is instructed to initiate rescheduling reviews for any Schedule I substance that successfully completes Phase 3 clinical trials for serious mental health disorders. While the DEA is already statutorily required to reschedule drugs within 90 days of FDA approval, the directive signals administration prioritization of this process for psychedelic compounds.

The order also directs agencies to reconsider enforcement approaches for drugs showing clinical promise, potentially affecting how the DEA handles research involving controlled substances. This builds on the HALT Fentanyl Act signed in 2025, which reformed research activities on Schedule I substances.

Scientific and Industry Response

Leaders of companies developing psychedelic therapies have emphasized that the executive order does not lower scientific standards for approval. Rob Barrow, CEO of Definium Therapeutics, stated that "nothing about any of this should lower the bar or the requirements for getting drugs approved and reviewed." Kabir Nath, CEO of Compass Pathways, noted that the presence of scientists emphasizing research quality at the signing ceremony was reassuring.

The administration appears to be moving quickly on implementation. Dr. Mehmet Oz, who leads the Centers for Medicare and Medicaid Services, indicated that the Center for Medicare and Medicaid Innovation is already considering new pricing models for psychedelic treatments, with potential announcements by year-end. The pricing structure would need to account for the fact that psychedelic therapy often requires medical professionals to administer treatment, unlike daily medications that patients take at home.

Veterans and Political Context

The signing ceremony highlighted the administration's focus on veterans, with the president flanked by Congressman Morgan Luttrell and his brother Marcus Luttrell, a former Navy SEAL, along with other veterans who reported positive responses to psychedelic treatment. More than 6,000 veterans die by suicide annually, and the administration has framed expanded access to psychedelic therapies as a moral obligation to those who served.

The order also reflects the influence of the Make America Healthy Again movement, which has advocated for expanded psychedelic access. Joe Rogan, the influential podcaster who has hosted Trump on his show, reportedly texted the president about ibogaine research, prompting a rapid response: "Sounds great. Do you want FDA approval? Let's do it."

Unanswered Questions

Legal scholars have noted that the executive order's actual impact may be more limited than its sweeping language suggests. The National Priority Voucher program already existed, and the "shall" language directing the FDA to provide vouchers still requires drugs to meet program criteria that leave considerable discretion to the commissioner. The Right to Try pathway for psychedelics remains legally contested, with the Ninth Circuit ruling against doctors seeking to use psilocybin under the Act in 2025.

Harvard's Petrie-Flom Center faculty director I. Glenn Cohen has raised questions about reimbursement and delivery models, noting that FDA approval alone will not ensure patient access if insurance does not cover treatment. The Risk Evaluation and Mitigation Strategy that FDA attaches to any approval will heavily determine whether psychedelic therapy resembles ketamine clinics—requiring medical supervision—or follows a more conventional prescription model.

The order also does not address religious use of psychedelics, which has generated significant legal activity as psychedelic churches seek protection under Religious Freedom Restoration Acts. This omission suggests the administration is prioritizing the FDA regulatory pathway over other access routes.

What Comes Next

For patients and families struggling with treatment-resistant mental illness, the executive order represents hope—but not immediate relief. Clinical trials will continue, regulatory reviews will proceed, and the scientific process will determine which compounds demonstrate sufficient safety and efficacy for approval. The $50 million in federal funding, while symbolically significant, represents a modest investment in the context of pharmaceutical research costs.

Yet the policy shift is unmistakable. A federal administration that has historically emphasized drug enforcement is now actively promoting research into substances classified as Schedule I controlled substances. For researchers who have spent decades investigating psychedelic therapies, often facing institutional resistance and funding challenges, this reversal marks a watershed moment that could accelerate the development of treatments for some of psychiatry's most intractable conditions.